HC Wainwright reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reissued an overweight rating and set a $6.00 price target on shares of Lineage Cell […]
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.00 price target on shares of […]
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) Director Broadwood Partners, L.P. bought 6,730,770 shares of Lineage Cell Therapeutics stock in a transaction on Tuesday, February 6th. The stock was acquired at an average price of $1.04 per share, for a total transaction of $7,000,000.80. Following the purchase, the director now owns 41,666,255 shares […]